Literature DB >> 17210943

Cancer care, money, and the value of life: whose justice? Which rationality?

Daniel P Sulmasy1.   

Abstract

Cost-containment in oncology is a moral issue. While economists use the word "rationing" to describe all limitations on resource utilization that result from human choice, the ordinary language distinction between allocation and rationing is morally meaningful and can help oncologists to determine their proper moral role in cost-containment. It is argued that oncologists should not be required to ration at the bedside, nor should they be given financial incentives to practice frugally, nor should they be subjected to a variety of bureaucratic mechanisms to control costs indirectly. In addition, it is argued that the fact that treatments have a price does not logically imply that patients have a price. Cost-effectiveness analysis is often suggested as a means of deciding how best to allocate resources, but some of its many ethical limitations are discussed. The alternative is an open, public, participatory process about how to ration care, abandoning the formulaic pretenses of cost-effectiveness analysis, but with a commitment to reason, good will, and common sense. Oncologists would then be free to advocate for their patients within the constraints imposed by this public process.

Entities:  

Mesh:

Year:  2007        PMID: 17210943     DOI: 10.1200/JCO.2006.08.0481

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Ethical challenges: caring for the underinsured, geographically disadvantaged patient.

Authors:  Elizabeth C Riley; Beverly Moy
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840

2.  A model to estimate human resource needs for the treatment of outpatients with cancer.

Authors:  Gianpiero Fasola; Giuseppe Aprile; Marianna Aita
Journal:  J Oncol Pract       Date:  2011-11-29       Impact factor: 3.840

3.  In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.

Authors:  Peter A Ubel; Scott R Berry; Eric Nadler; Chaim M Bell; Michael A Kozminski; Jennifer A Palmer; William K Evans; Elizabeth L Strevel; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

4.  Private Practice Administrative Costs Influenced by Insurance Payer Mix.

Authors:  Jorge M Luna; Paul W Thurman; Margaret Wolfe; Daniel Yagoda; Edward Reed; William D Figg
Journal:  J Oncol Pract       Date:  2009-11       Impact factor: 3.840

5.  "Well, I think there is great variation...": a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer.

Authors:  Jan Schildmann; Jacinta Tan; Sabine Salloch; Jochen Vollmann
Journal:  Oncologist       Date:  2013-01-03

6.  Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control.

Authors:  Jeanne S Mandelblatt; Anna N A Tosteson; Nicolien T van Ravesteyn
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

7.  The moral psychology of rationing among physicians: the role of harm and fairness intuitions in physician objections to cost-effectiveness and cost-containment.

Authors:  Ryan M Antiel; Farr A Curlin; Katherine M James; Jon C Tilburt
Journal:  Philos Ethics Humanit Med       Date:  2013-09-08       Impact factor: 2.464

8.  Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan.

Authors:  Takeshi Ebara; Tatsuya Ohno; Takashi Nakano
Journal:  Daru       Date:  2013-05-25       Impact factor: 3.117

9.  Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study.

Authors:  Gianpiero Fasola; Marianna Aita; Luisa Marini; Alessandro Follador; Marina Tosolini; Laura Mattioni; Mauro Mansutti; Andrea Piga; Silvio Brusaferro; Giuseppe Aprile
Journal:  BMC Health Serv Res       Date:  2008-04-01       Impact factor: 2.655

10.  A North-European perspective challenges the UK NICE system for resource allocation.

Authors:  Silvia Camporesi
Journal:  Ecancermedicalscience       Date:  2010-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.